Clinical Trial Search

Primary: Change in Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score — 3.2; 2.5 score on a scale — p=0.53

Primary: Change From Baseline in Neuropsychiatric Inventory (NPI) Psychosis Subscale Score at Week 10 in Acute Phase — 12.12; 12.29; -5.52; -6.55 Units on a scale — p=0.802

Primary: Relapse by Study Week 32 — 15; 8; 24 participants — p=0.02

Primary: Antipsychotic Efficacy — -1.93; -3.76 Score on the NPI-NH scale — p=0.0451

Primary: Symptoms of Agitation as Measured by the Pittsburgh Agitation Scale — 7.14; 5.55; 5.69; 4.97 score on a scale — p=.015

Primary: Mean Clinical Global Impression of Change (CGIC) at Last Observation — 2.6; 4.5 units on a scale

Primary: Evaluations of Behavioral Disorders — 68; 66; 36; 69 Scores on a scale — p=1

Primary: Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change — 2.5; 2.43 units on a scale

Primary: ADCS-Clinical Global Impression of Change in Agitation (ADCS-CGIC-A) — 3.434; 3.442 score on a scale — p=0.9904

Primary: Change From Baseline to Week 16 in Modified Functional Status Questionnaire (mFSQ) Total Score — 14.0 score on a scale — p=<0.0001

Primary: Number of Participants Who Experienced an Adverse Event (AE) — 3; 8; 5; 1 Participants

Primary: Time From Randomization to Relapse in the Double-blind (DB) Period — NA; NA days — p=0.0023

Primary: Presence of Agitation and/or Psychosis Measured by the Neuropsychiatric Inventory (NPI) Combined With an Assessment of the Clinical Significance of Behavioral Change…

Primary: Change From Baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score — 73.7; 68.8; 71.3; -16.2 score on a scale — p=0.789

Primary: Stage 1 and Stage 2: Change From Baseline in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score to Week 6 and Week 12 — 73.9; 72.3; 71.7; -10.7 units on a…

Primary: Word List Memory Total - ADAS-cog — 14.35; 14.7; 15.1; 14.67 Words recalled

Primary: Change in CMAI Total Score — -15.4; -10.0; -11.5 score on a scale — p=0.010

Primary: Incidence of Hospital Transfers (Patients) — 0.99; 1.12 events per person day at risk — p=0.522

Primary: Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment. — 0.35; 0.20; 0.26; 0.32 z-score — p=0.3236

Primary: Mean Change From Baseline in the 4-Item Agitation/Aggression Subscale of the Neuropsychiatric Inventory (NPI-4 A/A) at Week 12 — -5.4; -6.2 units on a scale

Primary: Mini-mental State Examination (MMEE) — 12; 12 score — p=0.23

Primary: Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment. — 0.13; 0.17; 0.16; 0.01 Z-score — p=0.7907

Primary: Change From Baseline In The Cohen-Mansfield Agitation Inventory (CMAI) Total Score After 12 Weeks Of Brexpiprazole Treatment — -21.6; -17.6; -17.8 units on a scale…

Primary: Antipsychotic Efficacy — -5.9; -5.8; -6.7; NA Score on the SAPS H+D scale

Primary: Antipsychotic Efficacy — -4.4; NA; -6.5; NA Scores on the SAPS H+D scale

Primary: Change in Connectivity Measure of the TGd Parcellations. — 0.5 abnormal connections

Primary: Time to Dispensing of Inappropriate Medication Prescription — 76.7; 77.9; 77.5 Percentage of Cumulative Incidence — p=0.76

Primary: Treatment Emergent Adverse Events (TEAEs) — 53 Participants

Primary: Safety and Tolerability of Multiple Ascending Doses of Posiphen: Reports of Adverse Events or Study Discontinuations — 0; 0; 0; 0 events

Primary: Change From Baseline in Cohen-Manfield Agitation Inventory(CMAI) Score at 10 Weeks After Dosing. — -11.7; -15.2; -8.0 units on a scale — p=< 0.0001